Document text
Principal Investigator: Heinrich Feldmann
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2022
Award: $5,627,958
Funding agency: National Institute of Allergy and Infectious Diseases
Mammarenaviruses
Introduction: Lassa virus (LASV) is an enveloped, bisegmented, ambisense RNA virus and the cause of Lassa fever (LF) in humans. The natural reservoir of LASV is a small peri-domestic rodent, Mastomys natalensis. LASV is found across sub-Saharan West Africa with Guinea, Sierra Leone, Liberia and Nigeria historically reporting the vast majority of all LF cases. For this WHO priority pathogen there are no licensed vaccines or treatment options. (review Hansen et al., Microorganism 2021)
Findings: We evaluated peptide-conjugated morpholino oligomer (PPMO) as a treatment option for LASV infection. Like siRNA, these oligomers are designed to bind mRNA and thus block translation of viral proteins. We have successfully tested PPMOs against LASV infection in cell culture and are preparing to test the efficacy in the guinea pig model Rosenke et al., unpublished.
We have continued the use of the cynomolgus macaque model of LF to test both therapeutics and vaccines against LASV infection. A high dose of favipiravir was evaluated as a treatment for LASV and completely protected cynomolgous macaques against disease. Surprisingly, all animals treated with the anti-viral ribavirin succumbed to disease (Lingas et al., PLoS Comp Bio 2021). We have also tested a LASV entry inhibitor (LHF-535) in collaboration with Kineta Inc. These studies resulted in a near 70% survival in cynomolgus macaques infected with a lethal dose of LASV (Rosenke et al., unpublished).
We continued to characterize Mastomys natalensis as a laboratory model for LASV. We have performed LASV infection studies to determine immune responses, viral kinetics, and transmission in Mastomys (Safronetz et al., Viruses 2021; Smith et al., Lab Anim 2021; Tang-Huau et al., Viruses 2021).
We have continued to characterize the VSV-LASV vaccine in preclinical studies. A GMP produced seed stock showed complete protection against lethal LASV challenge in the cynomolgus macaque model (Rosenke et al., unpublished). We are currently evaluating a cytomegalovirus (CMV) based LASV vaccine platform to be used as a disseminating vaccine in the reservoir species Mastomys natalensis. Studies are underway to establish protection against LASV infection though dissemination of the vaccine among Mastomys Jarvis et al., unpublished.
Orthonairoviruses
Introduction: Crimean-Congo hemorrhagic fever virus (CCHFV) is a tri-segmented, negative sense virus in the Bunyavirales order. The principal vector and reservoir are ticks of the Hyalomma genus and the wide geographic distribution of CCHFV follows the geographic range of these ticks. The primary routes of exposure are tick-bites and handling of infected livestock, although human-to-human spread is reported. Clinically, CCHF presents initially as a non-specific febrile illness that can rapidly progress to a severe, sometimes fatal hemorrhagic disease. The host and viral determinants of CCHFV pathogenesis are poorly understood and there are no approved vaccines or antivirals. (reviews Leventhal et al., Viruses 2021; Sergio et al., Antiviral Res 2022)
Findings: We developed the first immunocompetent mouse model for CCHF based on a mouse-adapted variant (MA-CCHFV) isolated using a serial passage approach. In this model, infection of wild-type C57BL/6 mice results in disease similar to humans with high viral loads, liver pathology and inflammatory responses (Hawman et al., eLife 2021).
We evaluated candidate vaccines for CCHFV in both rodents and NHPs. In collaboration with our European partners we evaluated a DNA-based vaccine for CCHFV in the macaque model. We found that prime-boost-boost vaccination with plasmids expressing the nucleoprotein (NP) and glycoprotein precursor (GPC) of CCHFV conferred substantial protection against CCHFV infection with significantly reduced viral loads and protection from liver pathology and clinical disease (Hawman et al., Nat Microbiol 2021). In a follow-up study we accelerated the vaccine approach to a two-dose vaccination regimen. Our data show that the DNA vaccine confers robust protection against CCHFV and suggest that both humoral and cellular immunity contribute to optimal vaccine-mediated protection (Hawman et al., under review). More recently, we have developed a replicating RNA vaccine expressing NP and GPC that mediated complete protection against clinical disease. Interestingly, vaccination resulted in antibodies against NP and cellular immunity against the virion-exposed GPC (Leventhal et al., eBioMed 2022).
In our mouse model recapitulating human convalescence we identified T-cells and IFN as essential for controlling the infection. We also determined that prior infection with CCHFV protected against reinfection with a distinct CCHFV strain (Hawman et al., Microorganisms 2021). In our MA-CCHFV model, we identified that both type I IFN and adaptive immunity are required for control of the virus. Interestingly, we also identified a significant sex-linked bias with female mice largely resistant to severe disease. The distinct disease outcomes in male versus female mice correlates with similar signs as is reported in human CCHF cases (Hawman et al., eLife 2021).
Filoviruses
Introduction: Infections with ebolaviruses and marburgviruses, family Filoviridae, cause Ebola (EVD) and Marburg virus disease (MVD), respectively, with high case fatality rates. The natural reservoirs for filoviruses are likely different bat species. Filovirus are enveloped, non-segmented, negative-stranded RNA viruses expressing seven structural proteins. The virion surface displays glycoprotein (GP) trimers that facilitate virus entry by receptor binding and fusion with target cells. The West African EVD outbreak has led to the licensure of vaccines treatments making EVD a success story in the field of neglected tropical diseases. (review Hansen et al., Expert Opin Investig Drugs 2021)
Findings: We continued our efforts to study filovirus replication and protein function and their role in immunology and pathogenesis (Bhatia et al., Vaccines 2021). We achieved a milestone by establishing a disease model for Reston virus (RESTV) where young pigs developed a respiratory disease that was rapidly fatal (Haddock et al., Proc Natl Acad Sci USA 2021). The model will be crucial to gain further insight into the pathogenesis and for countermeasure development. Furthermore, we could assign a role for the EBOV soluble glycoprotein in pathogenesis by activating the MAP kinase signaling pathway (Furuyama et al., PLoS Pathog 2021).
We have refined our filovirus VSV vaccines. Regarding vaccine safety, we tested the VSV-EBOV vector in pigs (VSV-susceptible livestock species). In collaboration with Kansas State University we could demonstrate that high-dose VSV-EBOV can indeed cause vesicular disease in pigs, but horizontal transmission was not observed providing further safety data for this vaccine (Morzonov et al., Emerg Micobes Infect 2021). We developed second-generation VSV vectors based of the licensed VSV-EBOV. This followed the concept of utilizing the EBOV GP entry mechanism to deliver a second immunogen to favorable immune cells. To avoid skewing the immune response towards the EBOV GP, we determined the domains needed for entry deleting highly immunogenic domains on the EBOV GP (Bhatia et al., Vaccines 2021). Based on this data, we produced a bivalent VSV-EBOV-KFDV(preM/E) vector that provided efficient protection against KFDV challenge in the previously established mouse model (Bhatia et al., Emerg Microbes Infect 2021; Bhatia et al., NPJ Vaccines 2021).
In collaboration we contributed to an important study that established rather minimal impact of intensive care on the outcome of EBOV infection in macaques further indicating the need of specific treatments for EVD Biondi et al., Microorganisms 2021).
Terms: <1-Beta-D-ribofuranosyl-1,2,4-triazolo-3-carboxamide><1-Beta-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide><Africa><African><Alpha Virus><Alphavirus><Animal Model><Animal Models and Related Studies><Animals><Antibodies><Antigens><Antiviral Agents><Antiviral Drugs><Antivirals><Area><Arenaviridae><Arenavirus><Arenavirus group><Bats><Binding><Biology><Bionomics><Bleeding><Breeding><Bunyavirales><Bunyavirus><C57BL/6 Mouse><CMV><COVID crisis><COVID epidemic><COVID pandemic><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 public health crisis><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 pandemic><COVID19 public health crisis><Caprine Species><Case Fatality Rates><Cell Body><Cell Culture Techniques><Cell Mediated Immunology><Cell-Mediated Immunity><Cells><Cellular Immunity><Chiroptera><Clinical><Collaborations><Common Rat Strains><Communicable Diseases><Congo Virus><Congo Virus Infection><Congo hemorrhagic fever virus><Congo-Crimean Hemorrhagic Fever><Containment><Convalescence><Coronaviridae><Coronavirus><Crab-Eating Macaque><Crab-Eating Monkey><Crimean Hemorrhagic Fever><Crimean Hemorrhagic Fever Virus><Crimean-Congo Hemorrhagic Fever Virus><Crimean-Congo hemorrhagic fever orthonairovirus><Cynomolgus Monkey><Cynomolgus macaque><Cytomegalovirus><DNA><DNA Vaccines><Data><Deoxyribonucleic Acid><Development><Diagnostic><Diagnostic tests><Disease><Disease Outbreaks><Disease Outcome><Disease model><Disorder><Dose><Drugs><Dysfunction><EBOV><Ebola><Ebola virus><Ebola-like Viruses><Ecology><Emergencies><Emergency Situation><Emerging Communicable Diseases><Emerging Infectious Diseases><Epidemiology><European><Family><Family suidae><Farm Animal><Female><Ferrets><Fever><Filoviridae><Filovirus><Follow-Up Studies><Followup Studies><Fostering><Frankfurt-Marburg Syndrome Virus><French Guinea><Functional disorder><Funding><Generations><Genome><Geographic Distribution><Geography><Glycoproteins><Goals><Goat><Goats Mammals><Group A Arboviruses><Guinea><HCMV><Hemorrhage><Horizontal Disease Transmission><Horizontal Transmission><Human><Humoral Immunities><IFN><Immune><Immune response><Immunes><Immunization><Immunocompetent><Immunologic Sensitization><Immunologic Stimulation><Immunological Sensitization><Immunological Stimulation><Immunological response><Immunology><Immunostimulation><In Vitro><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Inflammatory Response><Intensive Care><Interferons><International><Ixodida><Kansas><Kinetics><Laboratories><Lassa Fever><Lassa disease><Lassa fever virus><Lassa virus><Liberia><Licensure><Link><Lipids><Liver><Livestock><M fascicularis><M. fascicularis><MAP Kinase Signaling Pathways><Macaca><Macaca fascicularis><Macaque><Mali><Marburg><Marburg Virus Disease><Marburg hemorrhagic fever><Marburg virus><Marburg-like Viruses><Marburgvirus><Mastomys><Mediating><Medication><Messenger RNA><Mice><Mice Mammals><Microbe><Modeling><Modern Man><Molecular><Molecular Interaction><Murine><Mus><NIAID><NIH><Naked DNA Vaccines><Nanostructures><National Institute of Allergy and Infectious Disease><National Institutes of Health><Nigeria><Non-Polyadenylated RNA><Nucleoproteins><Orthobunyavirus><Outbreaks><Outcome><Ovine><Ovis><Pathogenesis><Pathogenicity><Pathology><Peptides><Pharmaceutic Preparations><Pharmaceutical Preparations><Physiopathology><Pigs><Plant Embryos><Plant Zygotes><Plasmids><Play><Politics><Process><Public Health><Pyrexia><RESTV><RNA><RNA Gene Products><RNA Viruses><RNA amplification><RNA vaccine><RNA-based vaccine><Rat><Rats Mammals><Rattus><Recombinant DNA Vaccines><Recombinants><Regimen><Replication Unit><Replicon><Reporting><Research><Research Activity><Research Institute><Resistance><Respiratory Disease><Respiratory System Disease><Respiratory System Disorder><Reston Ebola virus><Reston ebolavirus><Reston virus><Ribavirin><Ribonucleic Acid><Ribovirin><Rift Valley Fever><Rodent><Rodentia><Rodents Mammals><Role><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV2 epidemic><SARS-CoV2 pandemic><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><Safety><Salivary Gland Viruses><Security><Seeds><Serial Passage><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Sheep><Short interfering RNA><Sierra Leone><Site><Small Interfering RNA><Structural Protein><Suidae><Surface><Swine><System><T-Cells><T-Lymphocyte><Technology><Testing><Therapeutic><Ticks><Translations><Transmission><Tribavirin><Uganda><United States National Institutes of Health><Universities><VSV><Vaccination><Vaccines><Variant><Variation><Vector-borne disease><Vector-borne infectious disease><Vector-transmitted disease><Vector-transmitted infectious disease><Vesicular Stomatitis Virus><Vesicular stomatitis Indiana virus><Viral><Viral Burden><Viral Diseases><Viral Gene Products><Viral Gene Proteins><Viral Hemorrhagic Fevers><Viral Load><Viral Load result><Viral Pathogenesis><Viral Proteins><Virion><Virus><Virus Diseases><Virus Particle><Work><Zoonoses><Zoonotic><Zoonotic Infection><adaptive immunity><anti-viral agents><anti-viral compound><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-virals><antibody-based immunity><antiviral compound><antiviral medication><antiviral therapeutic><base><blood loss><cell culture><cell cultures><communicable disease transmission><corona virus><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><cytomegalovirus group><design><designing><developmental><disease transmission><disorder model><drug/agent><ebolavirus><efficacy testing><epidemiologic><epidemiological><exposure route><febrile><febris><guinea pig model><hemorrhagic fever><hepatic body system><hepatic organ system><host response><immune competent><immune system response><immunogen><immunogenic><immunoresponse><in vivo><infectious disease transmission><inhibitor><innovate><innovation><innovative><insight><international center><mRNA><mRNA vaccine><mRNA-based vaccine><male><microorganism><model of animal><model organism><mouse model><murine model><nano-structures><neglect><neglected tropical diseases><new vaccines><next generation vaccines><non-human primate><nonhuman primate><novel vaccines><outcome following vaccination><outcome following vaccine><pathogen><pathogenic virus><pathophysiology><plasmid vaccine><porcine><pre-clinical study><preclinical study><priority pathogen><protein function><receptor binding><receptor bound><research facility><resistant><response><result following vaccination><result following vaccine><reverse genetics><seed><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><sex><siRNA><social role><success><suid><therapeutic vaccine><thymus derived lymphocyte><tick bite><transmission process><treatment vaccines><vaccination outcome><vaccination result><vaccine candidate><vaccine for the treatment><vaccine for treatment><vaccine outcome><vaccine platform><vaccine result><vaccine safety><vector><vector vaccine><vector-borne illness><vectorborne disease><vectorborne illness><vectorborne infectious disease><viral infection><viral pathogen><virus host interaction><virus infection><virus pathogen><virus pathogenesis><virus protein><virus-induced disease>